Purpose: Individual genetic variation can affect both
pain expression and
opioid response. Large cohort datasets are required to validate evidence influencing genomic factors in
opioid response. This study examined the feasibility of establishing an
opioid pharmacogenomics registry for
cancer patients containing longitudinal matched clinical, symptom, pharmacological, and genomic data, with an a priori feasibility target of 50 participants within 12 months. Methods: Consecutive patients with advanced
cancer receiving
opioids across five
palliative care services were recruited. Clinical data (demographics,
pain data, adverse effects, medications) and blood (
DNA,
RNA, pharmacokinetics) were collected over two time points. Patient and clinician qualitative interviews were conducted to assess acceptability. This study was approved by the SVHA Ethics Committee, Melbourne, Australia (HREC 252/18). Results: Enrollment for the registry was deemed feasible. Fifty-eight participants were recruited (median age 63.7, 45% female, 83% complete data), with the most frequent diagnosis being
lung cancer (n = 18, 33%) and
oxycodone the most frequently prescribed
opioid (n = 30, 52%). Qualitative data indicated positive engagement from both patients and clinicians. Conclusion: Establishing a longitudinal
opioid pharmacogenomic registry in patients with
cancer receiving
palliative care is feasible and readily acceptable.